Substitution treatment of drug dependence - Legal basis and recent results of therapy research;Substitutionsbehandlung drogenabhängiger: Rechtliche grundlagen und neue ergehnisse der therapieforschung

Nervenheilkunde

Volumn 25, Issue 4, 2006, Pages 286-294

  Soyka, Michael ^a,b,c   Banzer, K ^a   Erbas, B ^b   Koller, G ^a   Backmund, M ^d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Bayerische Akademie für Suchtfragen in Forschung und Praxis BAS e V   (Germany)

^c Privatklinik Meiringen   (Switzerland)

^d Klinikum Schwabing   (Germany)

Author keywords

Buprenorphine; Comorbidity; Drug dependence; Hepatitis; Methadone; Substitution

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BUPRENORPHINE; CARBAMAZEPINE; CODEINE; DIPIVOXIL; HESPERA; LAMIVUDINE; LEVO ALPHA ACETYL METHADON; LEVOMETHADONE; METHADDICT; METHADONE; MORPHINE; NALOXONE; NALTREXONAZINE; NEMEXIN; OPIATE; PHENOBARBITAL; PHENYTOIN; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

DRUG DEPENDENCE; DRUG FORMULATION; DRUG SUBSTITUTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGAL ASPECT; MEDICAL RESEARCH; PHARMACIST ATTITUDE; REVIEW;

EID: 33750914608     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626467     Document Type: Review

References (47)

1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination of buprenorphine-naloxone tablet. Drug Alcohol Depend 2000; 58: 143-52.
2. Arzneimittelkommission der deutschen Ärzteschaft. Auftreten von Kammertachykardien (Torsade de pointes) nach hoch dosierter Gabe von Methadon. Dt. Aerzteblatt 2002; 99, B2831.
3. Backmund M. Diagnostik der Drogenabhängigkeit. Internist 1999; 40: 597-600.
4. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
5. Backmund M, Schütz CG, Meyer L, Eichenlaub D, Soyka M. Alcohol consumption in heroin, methadone-substituted and codeine-substituted patients- frequency and correlates of use. Eur Addict Res 2003; 9: 45-50.
6. Backmund M, Meyer K, Wächtler M, Eichenlaub D. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18: 563-8.
7. Backmund M, Meyer K, Edlin B. Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users. Clin Infect Dis 2004; 39: 1540-3.
8. Backmund M, Henkel C, Jordan F, Habsch J, Meier K, Kääb S. Das QT-Intervall während der Substitutionsbehandlung Heroinabhängiger. Suchtmed 2005; 7: 161-4.
9. Backmund M, Meyer K, Henkel C, Reimer J, Wächtler M, Schütz CG. Risk factors and predictors of human immunodeficiency virus infection among injection drug users. Eur Addict Res 2005; 11: 138-44.
10. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis 2005; 40 (suppl 5): S330-5.
11. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001; 96: 683-90.
12. Bickel WK, Amass L, Crean JP et al. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology 1999; 146: 111-8.
13. Buehringer G, Kroeger C, Kuefner H et al. Substance abuse research network ASAT: allocating substance abuse treatments to patient heterogeneity (in German). Suchtmed 2004; 6: 7-13.
14. Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacology 2004; 14: 209-16.
15. Dittert S, Naber D, Soyka M. Methadonsubstitution und Fahrtauglichkeit - Ergebnisse einer experimentellen Studie. Nervenarzt 1999; 70: 457-62.
16. Dole VP, Nyswander M. Medical treatment of diacetylmorphine (heroin) addiction. JAMA 1965; 193: 646-50.
17. EASL International consensus conference on hepatitis B. Consensus statement. J Hepatol 2003; 38: 533-40.
18. Erbas B, Tretter F, Wolstein J. Behandlung von Opiatabhängigkeit rund um die Geburt. Ergebnisse einer Diskussion der BAS e.V. Publikationen/Papiere 2004: www.bas-muenchen.de
19. Fahrmbacher-Lutz C (Hrsg.). Suchtberatung in der Apotheke. Stuttgart: Deutscher Apothekerverlag 2000.
20. Gastpar M, Heinz W, Joehlke Th, Raschke P. Glossar: Substitutionstherapie bei Drogenabhängigen (2. Aufl.). Berlin, Heidelberg, New York: Springer Verlag 2002.
21. Havemann-Reinecke U, Küfner H, Schneider U et al. AWMF-Leitlinien: Postakutbehandlung bei Störungen durch Opioide. Sucht 2004; 50: 226-57.
22. Hoffmann C, Rockstroh J, Kamps B. HIV-Medizin 2005. www.HIVMedicine.com.
23. Hurley SF, Jolley DJ, Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997; 349: 1797-800.
24. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend 2003; 21: 87-101.
25. Kagerer S, Backmund M, Walcher S, Soyka M. Substitution mit Buprenorphin und Fahrtauglichkeit - Ergebnisse einer experimentellen Untersuchung. Suchtmed 2002; 4: 17-24.
26. Kakko J, Svanborg KD, Kreek MJ et al. 1-year retention and social function after buprenorphine-assisted relapse prevention for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 2003; 361: 662-8.
27. Krausz M, Degwitz P, Haasen C, Verthein U. Opioid addiction and suicidality. Crisis 1996; 17: 175-81.
28. Krausz M. Substitutionsbehandlung. In: Krausz M, Haasen C, Naber D, Hrsg.: Pharmakotherapie der Sucht. Karger Verlag, Freiburg-Basel 2003; 105-58.
29. Kuefner H, Hackmann et al. Optimizing substitution treatment in drug dependence (OSTD): Withdrawal symptoms and Craving during the first week (in German). Suchtmed 2004; 6: 95.
30. Ling W, Charavustra C, Collins JF et al. Buprenorphine maintance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction 1998; 93: 475-86.
31. Ling W, Wesson DR, Charuvasta C et al. A controlled trial comparing buprenorphine and methadone maintenance opioid dependence. Arch Gen Psychiatry 1996; 53: 410-17.
32. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev Jan 2005, 25: CD004330
33. Mintzer MZ, Stitzner ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 2002; 67: 41-51.
34. Nickel T, Sonntag A, Backmund M, Pollmächter T. Depression during therapy with Interferon-alpha - how long should an antidepressant treatment last? Pharmacopsychiatry 2005; 38: 102-4.
35. Penning R, Betz P, v.Meyer L, Soyka M. Drogentodesfälle mit Methadonbeteiligung. Nervenheilkunde 1992; 4: 183-6.
36. Pirnay S, Borron SW, Giudicelli CP et al. A critical review of the causes of death among most-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99: 978-88.
37. Pollack H, Heimer R. The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C. In: Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L (Hrsg.) EMCDDA Monographs 7: Hepatitis C and injecting drug use: impact, costs and policy options. European Monitoring Centre for Drugs and Drug Addiction 2004, Lissabon: 345-67. www.emcdda.eu.int.
38. Reimer J et al. Guidelines for Treatment of Hepatitis C Virus Infection in Injecting Drug Users: Status Quo in the European Union Countries. Clin Infect Dis 40 Suppl 2005, 5: S373-8.
39. Schäfer M et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2005; 37: 443-51
40. Soyka M, Banzer K, Buchberger R, Völkl M, Naber D. Methadon-Substitution Opioidabhangiger - Katamnestische Ergebnisse und klinische Erfahrungen eines 7jährigen wissenschaftlichen Forschungsprojekts. Nervenheilkunde 1997; 16: 347-52.
41. Soyka M, Hock B, Kagerer S, Lehnert R, Limmer C, Kuefner H. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients - Results of a randomized clinical trial. J Clin Psychopharmacol (in Druck).
42. Soyka M, Horak M, Dittert S et al. Less driving impairment on buprenorphine than methadone in drug-dependent patients? J Neuropsychiatry Clin Neurosci 2001; 13: 527-8.
43. Soyka M. Medikamenten- und Drogenabhängigkeit. Stuttgart: Wissenschaftliche Verlagsgesellschaft 1998.
44. Stempel K. Illegale Drogen/ Rauschgift - Zahlen und Fakten. In: DHS (Hrsg.) Jahrbuch Sucht 2005. Geestacht Verlag: 2005; 69.
45. Uchtenhagen A. Substitutionsbehandlung. In: Uchtenhagen A, Zieglgänsberger W: Suchtmedizin. München, Jena: Urban und Fischer 2000.
46. Wittchen HU et al. Buprenorphine and Methadone in the Treatment of Opioid Dependence: Methods and design of the COBRA Study. J Methods Psychiatry Res 2005; 14: 14-28.
47. Robert-Koch-Institut www.zct-berlin.de/Impfplan